A narrative review on the neurobiology of lucid dreaming: mechanisms and therapeutic potential.

Lucid dreaming—being aware of and controlling dreams—shows promise for reducing nightmares and alleviating symptoms of post-traumatic stress disorder and anxiety, though evidence remains preliminary. Neurobiological mechanisms involve activation of prefrontal and parietal brain areas, increased gamma oscillations, and cholinergic and dopaminergic signaling during REM sleep. Studies using objective verification methods such as eye movements and EEG/fMRI have examined clinical groups including people with PTSD, chronic nightmares, and Parkinson's disease, as well as healthy adults aged 18–45. Developments in portable EEG and virtual reality may refine research, but larger randomized trials with standardized induction techniques are needed to confirm long-term efficacy and safety.

Study at a glance

Abstract

Background: Lucid dreaming (LD), which involves being aware of and controlling one’s dreams, is of particular interest in the study of consciousness and has potential therapeutic applications. In this narrative review, we highlight the neurobiological aspects of LD, specifically its mechanisms associated with the activation of prefrontal and parietal areas, increased gamma oscillations, and the influence of cholinergic and dopaminergic signaling, primarily during rapid eye movement (REM) sleep. Objective: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams. Methods: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson’s] and healthy individuals (18–45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated. Results: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns. Conclusion: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.